BOSTON SCIENTIFIC CORP vs ResMed Inc., two Medical Devices stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BSX and RMD diverge most: on debt / equity, BSX reads 0.00 and RMD reads 0.10; on implied growth (priced in), BSX reads +4.1% and RMD reads +11.3%. The rest of the comparable metrics sit closer together. On valuation, today's BSX price has a different growth bar priced in than RMD (+4.1% implied for BSX vs +11.3% for RMD); the higher figure is the steeper assumption to clear, not a better or worse stock. What BSX's price implies is a bet that sits within the historical range (whole-company basis). What RMD's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | BSX | RMD |
|---|---|---|
| Price | $46.73 | $211.00 |
| Market cap | $69.9B | $30.7B |
| Sector | Medical Devices | Medical Devices |
| Stage | Growth | Mature |
| Implied growth (priced in) | +4.1% | +11.3% |
| P/E | 19.6 | 20.4 |
| P/B | 2.68 | 4.74 |
| P/S | 3.39 | 5.55 |
| EV/EBITDA | 13.2 | 14.1 |
| Revenue growth | +17.6% | +10.3% |
| Gross margin | 69.5% | 62.3% |
| Operating margin | 21.2% | 34.9% |
| Net margin | 17.3% | 27.4% |
| Return on equity | 13.6% | 23.4% |
| Return on assets | 8.0% | 17.3% |
| Return on invested capital | 11.5% | 21.0% |
| FCF yield | 5.0% | 5.7% |
| Dividend yield | — | 1.0% |
| Debt / equity | 0.00 | 0.10 |
| Current ratio | 1.90 | 3.01 |
| Altman Z (solvency) | 6.88 | 8.30 |
| Piotroski F (quality) | 5 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.